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Abstract
Although several repair mechanisms have been de-
scribed in the human heart, all fall too short to prevent
clinical heart disease in most acute or chronic pathologi-
cal cardiac conditions. Moreover, despite many break-
throughs in cardiovascular medicine, the complications
of a myocardial infarction such as chronic heart failure
remains a serious worldwide problem.
Bone marrow stem cells could provide for a promising
strategy to restore myocardial infarctions and prevent
postinfarct congestive heart failure, because there is
growing body of evidence that bone marrow stem cells,
such as mesenchymal stem cells, can generate new car-
diomyocytes in animals and humans.
In this review, we will discuss important issues on stem
cell therapy for cardiac regeneration after myocardial
infarction, which might be of paramount importance
when considering future human trials.
Copyright © 2003 S. Karger AG, Basel
Introduction
It has been widely accepted that cardiac myocyte
hypertrophy is the most important compensation mecha-
nism of the heart to satisfy increased physiological de-
mands and or to adapt to pathological cardiac conditions.
On the other hand, there has been a strong belief that the
muscle cells of the adult heart cannot divide or replicate
under the same conditions [1].
However, recent reports have highlighted evidence on
the existence of cardiac cell renewal in either the normal
or diseased heart, but the clinical significance of this cell
renewal in several pathological conditions in humans
remains uncertain [2–4].
In the setting of myocardial infarction, for instance,
the compensatory replication of myocytes does not repair
the infarct area itself, but occurs at the border and at a
distance of the infarcted myocardium, leaving behind a
scar lesion whose size is a major determinant of morbidity
and mortality [5]. Although we might be able to enhance
this proliferative response in the future using pharmaco-
logical modulation or genetic manipulations of the car-
diac cell cycle, the cardiac regeneration process is likely to
be more complex than replicative enhancement as the
sole means of obtaining a scarless heart [6]. In addition,
cell cycle manipulations are likely to induce apoptosis,
tumor genesis and even cardiac myopathies [7, 8].
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Stem cells could provide an alternative biological strat-
egy to repair myocardial infarctions and prevent postin-
farct congestive heart failure, because there is a growing
body of evidence that bone marrow stem cells can gener-
ate new cardiomyocytes in animals and humans [9–12].
However, before we can claim that this regenerative strat-
egy in cardiovascular medicine is truly applicable in
humans, many hurdles must be overcome first.
In this review, we will critically discuss important
issues on stem cell therapy for cardiac regeneration fol-
lowing myocardial infarction, which might be of para-
mount importance when considering future human trials.
We will focus on the use of bone marrow stem cells, such
as hematopoietic or mesenchymal stem cells, which are an
accessible autologous source of stem cells and do not seem
to pose the ethical or immunological concerns inherent in
using embryonic stem cells. (1) The concept of stem cell
therapy will be highlighted and from a developmental
point of view, we will critically discuss (2) how stem cells
can be delivered to the infarct area. (3) We also summa-
rize possible hurdles regarding the transdifferentiation or
plasticity of stem cells towards cardiomyocytes once im-
planted in the heart. (4) Finally, the functional aspects of
the reconstituted heart will be considered and (5) poten-
tial adverse reactions will be addressed when envisaging
stem cells for myocardial regeneration.
A discussion of skeletal myoblasts for myocardial scar
repair or cell therapy in chronic heart failure is beyond the
scope of this review, and readers are referred to other arti-
cles for details [13–16].
Concept: Enhance Cardiac Regeneration Using
Bone Marrow Stem Cells
Several investigators have demonstrated that cardiac
injury in rodents (rats, mice) recruits bone marrow stem
cells with their migration to the injured area via the blood
stream and their subsequent differentiation into cardio-
myocytes [9–11]. Most of these models of stem cell plas-
ticity involved animals with experimental myocardial
infarctions, so that it is conceivable that stem cell homing
to the heart was in response to signals sent by the ischemic
and injured cardiac area [17]. This is in accordance with
the very low level of incorporation of stem cells in the
intact heart as compared to the injured heart [18]. Al-
though bone marrow-derived cardiomyocytes are also
present in the adult human heart in certain conditions,
the exact phenotype of these regenerating bone marrow
cells still remains to be determined and we do not know
yet whether such a repopulation of bone marrow-derived
cardiomyocytes observed in animals also occurs in the
context of myocardial infarction in humans [12].
How bone marrow stem cells are mobilized or traffick
to the injured heart is currently not known, but it is likely
to be regulated through sequential interactions with adhe-
sion molecules and chemokines such as stromal-cell-
derived factor-1 (SDF-1), which is upregulated after in-
farction [19, 20]. However, many of these mediators are
still unknown and some are likely to be expressed tran-
siently [21].
All experimental animal studies confirm that the fre-
quency at which the spontaneous cardiac incorporation
and regeneration occurs from migrated bone marrow
stem cells is very low and inadequate for a clinically rele-
vant regeneration of the injured heart [10, 11]. Therefore,
part of the concept of stem cell therapy must focus on the
characterization and augmentation of signals that home
stem cells to the heart in order to optimize cellular recruit-
ment and migration to the injured heart. Meanwhile,
investigators have isolated and cultured bone marrow
stem cells ex vivo such as mesenchymal and hematopoiet-
ic stem cells to increase cell dose for augmenting local
accumulation of transplanted stem cells in the infarct
area, irrespective of the possible quantitatively, spatially
or temporally restricted homing/adhesion signals [22, 23].
In addition, the exact number of bone marrow stem cells
needed to reconstitute an infarcted heart is not known
and before a sufficient graft size can be obtained in the
infarct area, these cells must first overcome different bio-
logical obstacles (e.g. ischemia, inflammation) following
myocardial infarction, which are known to reduce signifi-
cantly stem cell viability. This may require anti-death
strategies to improve stem cell survival/number in the
infarcted heart [24]. Although prosurvival strategies have
been proven successful, some of them might actually not
be suitable for human use [24–26].
Stem Cell Delivery
Therapeutic stem cells have been transplanted or mo-
bilized into the injured heart in different manners: (1) by
intravenous instillation; (2) by myocardial injections
either through the epicardium or the endocardium;
(3) through an intracoronary delivery system, or (4) using
cytokines to stimulate bone marrow [27].
The most appropriate route of stem cell administration
offers a high cell concentration in the damaged myocar-
dium and prevents ‘adverse’ homing to other organs. This
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optimal route is currently unknown because dose-graft/
effect studies comparing the different delivery modalities
are lacking and are difficult to obtain.
Intravenous Administration of Stem Cells
The intravenous route of administration seems to be
the least effective delivery method, because the coronary
blood flow makes up a small part of the normal cardiac
output and many circulation passages will be needed to
populate the infarct-related area [27]. In addition, adverse
homing of stem cells to other organs such as the lungs,
brain or spleen would be likely to occur especially when
intravenous stem cell delivery is used, because this seems
to be the most indirect pathway to the injured heart and
because of the lack of knowledge of the exact timing, sig-
nals or mechanisms that home the stem cells to the
infarcted myocardium.
Some reports even suggest that (considering hemato-
poietic stem cells) homing molecules might not be organ
specific, which also imposes a heart-selective delivery to
obtain an optimal cardiac graft size and limit adverse
homing [28]. In addition, it is currently not known wheth-
er ex vivo expansion of bone marrow stem cells to
increase cell dose may hamper their cardiac homing abili-
ty, as is seen in bone marrow homing [29, 30].
Myocardial Injections
Orlic et al. [22] have been able to repair infarction in
mice by injecting bone marrow stem cells into the border
zone of the infarct. The cells injected there reported to
migrate from the site of injection to the infarcted myocar-
dium and to reconstitute up to 68% of the infarct area.
However, these areas represent very small infarct areas
compared to infarctions in mammals such as humans pos-
sessing larger hearts. In this regard, stem cells injected
into the border zone are less likely to repair infarction to
the same extent in humans. This ‘size’ issue, among other
factors as well, clearly stresses the need for caution when
interpreting or extrapolating results from animal studies
(mostly on mice) to humans [31].
Direct delivery of stem cells using a intracoronary,
transendocardial or transepicardial approach could pro-
vide an alternative strategy to enhance cell engraftment
and optimal cell spreading into the infarct territory. How-
ever, the attempts to deliver stem cells directly into the
infarct area might bear a conceptual flaw, because the
inoculation of undifferentiated stem cells into the infarct
territory could move these cells away from host cardio-
myogenic signals, which are needed for optimal transdif-
ferentiation [32, 33]. In addition, some reports suggest
that the cardiac regeneration process in (some) verte-
brates and in cytokine-treated mice (see below) proceeds
from the border zone to the inside of the injured region,
which suggests that cell-to-cell contact with the peri-
infarct host cells may also be important for the cardiac
differentiation of undifferentiated stem cells [34–38].
Thus when direct injections into the infarct area are
considered, bone marrow stem cells may require prepro-
gramming in vitro to become committed to differentiate
into cardiomyocytes.
In fact, most experimental studies that used direct
intramyocardial injections have been performed with
myogenically committed cells, such as skeletal myoblasts,
5-azacytidine-treated mesenchymal stem cells or fetal car-
diomyocytes, which are less dependent on local signals for
cardiac differentiation [39–41]. However, intramyocar-
dial injections may injure the myocardium or induce
arrhythmias, and intramyocardial injections of myoblasts
produce islet-like formations which limits electromechan-
ical coupling with the host myocardium [27, 42].
Intracoronary Delivery
Although the safety and technical feasibility of intra-
coronary cell delivery has been demonstrated in patients
with myocardial infarction, its ability to disseminate stem
cells directly and globally in the infarct area remains
uncertain, because several animal studies suggest that
intravascularly delivered stem cells home in the peri-
infarct zone in contrast to those primarily inoculated into
the infarct area [10, 18, 33, 42, 43]. In other words, stem
cells are believed to migrate out of the vasculature in the
peri-infarct zone and than move to the infarcted area, in
the same manner as inflammatory cells home to the site of
myocardial infarction [33]. This indirect pathway could
limit an effective local accumulation. However, in most of
these studies, stem cell engraftment was assessed in ani-
mals with a permanently occluded infarct-related artery
or before native revascularization of the infarct territory
could have occurred, which could have limited direct cell
delivery to the infarct area [10, 18, 33]. On the other hand,
spatially and/or temporally restricted homing signals
could also explain why border zone rather than infarct
area engraftment might occur with intravascular delivery.
Nevertheless, the intracoronary delivery of stem cells
could offer a higher cell concentration than the intrave-
nous delivery route and seems to be less hazardous than
direct intramyocardial injections at the early infarct
stage.
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Cytokine Therapy
Cytokines and chemokines such as stem cell factor
(SCF), SDF-1 and its receptor CXCR4 are essential for
cardiogenesis during embryonic development in rodents
and are implicated in the recruitment of bone marrow
stem cells [19, 44]. The cytokine granulocyte colony-stim-
ulating factor (G-CSF or filgrastim) is also widely used in
humans to mobilize stem cells and progenitor cells from
the bone marrow to the blood stream [45]. Using this
cytokine and SCF in mice, Orlic et al. [38] demonstrated a
spectacular myocardial regeneration of the infarct area
with a definite hemodynamic and survival benefit as com-
pared to the controls. Although the investigators propose
that the cell responsible for cardiac regeneration after this
cytokine challenge might be a mobilized hematopoietic
bone marrow stem cell, it still remains speculative wheth-
er the regenerating cells in fact have a bone marrow ori-
gin. It also remains largely uncertain how granulocyte
monocyte-colony stimulating factor (GM-CSF) improves
collateral flow in patients with coronary artery disease
[46].
Nevertheless, these findings suggest that the use of
growth factors such as G-CSF might be eminently prag-
matic and could offer a noninvasive regenerative strategy
in patients with myocardial infarction. Clinical trials in
humans are currently under way to test whether the
administration of G-CSF is safe and could benefit pa-
tients with coronary artery disease (www.clinical-
trials.gov). However, caution is warranted because the
induction of granulocytosis in patients with myocardial
infarction during a course of G-CSF might contribute to
the development of myocardial reperfusion injury or
plaque destabilization at the remote, nonculprit coronary
lesions [45, 47, 48]. Additionally, the use of this cytokine
in humans might be ineffective when initiated at the time
of acute ischemia and infarction due to competition for
migration and receptor occupancy of the injured heart by
other cells such as neutrophils [21]. Furthermore, the
angiogenic effects of GM-CSF may also involve the vasa
vasorum of atherosclerotic plaques which might worsen
atherosclerotic disease. Documentation of a possible ath-
erogenic effect of GM-CSF, however, has been controver-
sial [46]. Finally, although the short-term clinical toxicity
in normal individuals seems acceptable, the long-term
effects of even a brief course of G-CSF in normal humans
are presently unknown [45].
Stem Cell Plasticity: How Do Stem Cells
Become Cardiomyocytes?
Real Transdifferentiation, Cell Fusion, Heterogeneity
of Stem Cell Populations? 
The making of Dolly the sheep and the multipotency of
adult stem cells have ultimately demonstrated the ‘ge-
nomic reprogrammability’ (plasticity) of cells in response
to altered cytoplasmatic or environmental factors [49–
51]. However, recent reports have challenged ‘stem cell
plasticity’ by demonstrating that stem cells are able to
alter their identity not by reprogramming to fit in their
new environment, but rather by fusion with preexisting
host cells. For instance, stem cells have been thought to
give rise to new hepatocytes in vivo, but genetic analysis
of these newly formed hepatocytes has revealed fusion of
stem cells with preexisting hepatocytes rather than their
transdifferentiation [52, 53]. This issue has stressed the
need for a better analysis of the reconstituted infarct to
distinguish between true differentiation or fusion of stem
cells with residual cardiomyocytes within the (peri-) in-
farct area [54]. However, the reports of cell fusion do not
contest all evidence on the existence of adult stem cell
plasticity and there is also indirect evidence that argues
against cell fusion as a major mechanism implicated in
‘cardiac regeneration’ [12, 55–57]. Moreover, some au-
thors hypothesize that fusion might even prevent resident
cells from dying and the fused cells could also be interme-
diates (followed by reduction divisions) in the regenera-
tion process [58, 59]. Finally, as will be discussed below,
stem cells can also improve cardiac function, apart from
bona fide cardiomyogenesis [60]. Nevertheless, caution is
needed because the formation of fused, hybrid cells with
extra chromosomes in patients treated with stem cells
could spur cancer [62].
Another unresolved issue concerns the remarkable het-
erogeneous developmental potential of undifferentiated
stem cells which replace all different cell types within the
heart (blood vessel cells, cardiomyocytes). This has not
yet been demonstrated at the single-cell level, because the
bone marrow populations used in most experimental
studies might have been impure enough to contain differ-
ent stem cell types (e.g. mixture of mesenchymal stem
cells, endothelial progenitors, a putative myocyte progeni-
tor) each having a restricted potential rather than the
reprograming of a single stem cell type towards the differ-
ent cell lines in the heart [63]. Even the current stem cell
sorting systems or purification protocols based on cell sur-
face markers such as CD34, Sca-1 or c-kit may yield a
heterogeneous selection of stem cells [63].
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A better identification assay and clonal analysis with
fate mapping of single-cell colonies cells could resolve this
issue and will enable us to compare the effectiveness of
different stem cell types and therefore give insight in the
best suited donor cell or direct us to a combination of dif-
ferent stem cells to rebuild the injured heart [39, 63].
Cardiomyogenic Signals for Transdifferentiation
Once implanted in the infarcted heart, local environ-
mental factors interact with the engrafted stem cells,
reprograming their genetic repertoire with resulting trans-
differentiation into cardiomyocytes. So there is cardiac
differentiation in response to organ- or tissue-specific
cues, called ‘milieu-dependent differentiation’. Most
mechanisms that mediate stem cell differentiation into
cardiomyocytes in vivo are as yet undetermined, but elec-
tromechanical stimulation and paracrine factors from
cardiac and other host cells are likely to be involved [32,
33, 64, 65]. Also contact with surrounding cells and extra-
cellular matrix may play a key role in stem cell grafting
and differentiation [37]. All these signaling pathways ini-
tiate the cardiac gene program, driving the stem cells to
differentiation into cardiomyocytes with the expression of
cardiac-specific proteins, such as cardiac troponin or ·-
myosin heavy chain (·-MHC) [22, 64]. The likelihood or
efficacy of cardiac differentiation probably depends on
the stem cell type used and the local quantitative and
qualitative cues encountered at the time of transplanta-
tion.
These local conditions or cues that dictate cardiac dif-
ferentiation in vivo, however, may not be sufficiently
strong to efficiently mediate lineage switch in the infarct
territory, as has been suggested by several studies [32, 33,
66]. Moreover, it is currently not known whether the ex
vivo expansion of stem cells could hamper their response
to cardiomyogenic signals.
These findings could force us to enhance the differenti-
ation signals in vivo or to use precommitted cells with car-
diogenic lineage instead of uncommitted or undifferen-
tiated stem cells [32, 66, 67]. The in vitro commitment of
undifferentiated stem cells to a cardiomyogenic cell line
has been performed by coculturing stem cells with cardio-
myocytes and END-2 cells or using myogenic agents such
as 5-azacytidine and many other chemicals [68, 69]. How-
ever, it is currently not known whether these cardiogenic
precommitment strategies are safe or could adversely
affect the cardiac homing ability of stem cells, their divid-
ing capacity or alternative differentiation into non-car-
diomyocytes, such as endothelial cells which make up an
important part of the cell population in normal cardiac
tissue. Whether these more differentiated cells will be
more effective than less differentiated or undifferentiated
cells should be investigated and an optimal differentiation
point determined.
Most attention has been focused on the renewal of
parenchymal cells (cardiomyocytes), but the restoration
of the extracellular matrix and vascular supply is also an
important issue because both tissue components are es-
sential for the structural and functional support of the
newly formed cardiomyocytes. For instance, neovascular-
ization of the infarct territory may be an important key to
successful cardiomyoplasty by any delivery method, be-
cause a suboptimal angiogenic milieu may limit the
engraftment, spreading, growth and differentiation of
stem cells in the infarct area. Although the normal cardiac
repair process involves neoangiogenesis, it is not clear
whether this would be sufficient for the above-mentioned
stem cell kinetics [70]. In addition, one should also take
into account the unfavorable dynamic changes in micro-
vessel density in infarct zones, as described in dogs, which
might also have a significant impact on the survival of the
newly formed cardiomyocytes [71]. Finally, from a chro-
nobiological point of view, we do not know whether we
should await for this pathological neovascularization to
have occurred before delivering stem cells, because the
process of neoangiogenesis is likely to proceed in close
temporal relationship with cardiomyocyte renewal, as
suggested from species with intrinsic cardiac regenerative
capacity and animals treated with stem cells [22, 35, 38].
Although stem cells by themselves can contribute to
neoangiogenesis and vasculogenesis of the infarct territo-
ry, additional genetic or cellular pro-angiogenic interven-
tions to improve infarct revascularization may be re-
quired [72–74]. As endothelial progenitors have been
demonstrated to colonize and contribute to angiogenic
sites in animal models, they could hold promise for
improved infarct revascularization and hence, cardiac
regeneration [75].
Time Window for Optimal Transdifferentiation
The fate or main differentiation pathway of engrafted
stem cells (cell death, cardiomyogenesis, neovasculariza-
tion or scar formation) is likely to be determined by the
local conditions at the time of implantation. In other
words, stem cells such as mesenchymal stem cells have
different fates, depending on the microenvironment they
engraft [33]. However, when stem cells are introduced
into the infarct area at the early stage of myocardial
infarction, a high cell death rate and therapeutic failure is
observed, which is due to inflammation and limited sur-
Stem Cells for the Heart,
Are We There Yet?
Cardiology 2003;100:176–185 181
vival factors (e.g. oxygen) in the early course following
infarction [24]. On the other hand, undifferentiated stem
cells such as mesenchymal stem cells might transdifferen-
tiate to fibroblasts in the fibrogenic microenvironment
when encountered at the time of scar formation, to which
they might even contribute and worsen the arrhythmic
substrate [11, 33, 76, 77]. Given these possible time con-
straints for optimal transdifferentiation after infarction
when undifferentiated stem cells are injected directly into
the infarct area, cell transplantation seems to be most suc-
cessful after the inflammatory reaction has resolved, but
before scar expansion [40]. However, the exact ‘time
point’ for stem cell transplantation after myocardial in-
farction is not known. Finally, the ‘exact delivery time’
not only relates to an optimal differentiation window, but
it also relates to the accessibility and the acceptance of the
infarct territory, which are determined by the homing and
adhesion signals, and the changing vasculature in healing
infarctions. But it is not known whether all these determi-
nants overlap, because little is known about the tissue and
molecular kinetics that mediate homing/adhesion and dif-
ferentiation of stem cells. Therefore, the understanding of
the evolution and maturation of the injured myocardium
at the molecular level will also be essential if today’s inter-
est in rebuilding the infarcted heart is to prove successful,
as has been formulated by Sun et al. [78].
The Repaired Infarction: Structural and
Functional Assessment
The in vivo cardiac developmental potential of adult
stem cells, such as mesenchymal stem, cells has been dem-
onstrated by labeling these cells genetically, which allows
transplanted cells to be readily identified upon histologi-
cal examination. These tracers have been colocalized with
cardiac specific markers such as cardiac troponin or tran-
scription factors such as Nkx 2.5 within the same cell to
establish cell origin as well as cell identity [79]. So far,
only histological and cytological analysis of tissue speci-
mens has enabled identification of the integration and dif-
ferentiation of implanted stem cells into the myocardium
[79]. Other techniques such as magnetic or radioactive
labeling of stem cells will enable us to identify and moni-
tor noninvasively in vivo stem cell migration, homing and
engraftment for future experimental studies [18, 80, 81].
Recent MRI studies in rats have demonstrated highly effi-
cient detection of labeled hematopoietic and mesenchy-
mal stem cells in vivo even at single-cell resolution [82].
Molecular imaging might broaden the horizon of nonin-
vasive monitoring in the future by assessing the cardiac
differentiation process of stem cells in the injured heart
[83].
In order to assess a successful cardiomyoplasty, it is
necessary to demonstrate that the transdifferentiated
stem cells in the infarct area are phenotypically like the
native, resident cells, but one should prove that these
transdifferentiated cells are also functional, improving
cardiac function. In most studies, however, besides newly
formed ‘mature’ cardiomyocytes, the regenerated infarct
area also consisted of ‘immature myocytes’ or ‘muscle-like
cells’, and vascular structures with endothelial and
smooth muscle cells, all derived from implanted bone
marrow stem cells [38]. Additionally, a disconcertingly
wide variability of cardiac stem cell engraftment and
repaired infarct area (0–90% of the infarct zone) has been
reported in the literature [22, 25]. This variability might
in part be attributed to the divergent experimental set-
tings, such as infarction model, animal size, number and
source of stem cell(s) used, but also the delivery time and
technique [24, 27, 40, 84]. Other reasons summarized in
reference 79, such as the technique used to track the fate
of the injected cells, may also account for the quantitative
differences between the reports [79].
Although short-term structural and functional im-
provement has been obtained in most of these animal
studies, the long-term viability and the chronic evolution
of the reconstituted heart and its response to physiological
and pathophysiological stimuli remains to be determined
[85].
In recent human trials, the increased viability of the
infarct area and enhanced dobutamine-responsive con-
tractility in some patients at follow-up has suggested the
propagation of cardiac cells following stem cell engraft-
ment, despite any histological proof [42, 43]. Other major
limitations of these trials relate to the low number of
patients included and the lack of randomized control
groups. Also, results from long-term follow-up are still
lacking and only surrogate endpoints could be evaluated
[85]. Finally, most human stem cell studies have been
done in patients that underwent simultaneous surgical or
percutaneous revascularization, so that the effectiveness
of stem cell transplantation may be confused with the
revascularization procedure and the spontaneous recov-
ery of stunned myocardium [86].
The suggested mechanisms by which stem cells im-
prove cardiac function after myocardial infarction in-
clude an active contribution to contractile function and/
or passive improvement of the heart mechanics [79]. Both
mechanism and other, as yet undetermined, influences as
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well seem to be mediated through direct and indirect cel-
lular or noncellular processes of the injected stem cells
[87, 88]. Noncellular effects, for instance, may include the
secretion of cytokines or growth factors by bone marrow
cells that may enhance the angiogenic repair process fol-
lowing myocardial infarction [88, 89].
According to Laplace’s law, the introduction of cells
that improves ‘infarct scar thickening’ may prevent left
ventriculardilatation and attenuate left ventricular wall
stress and remodeling after myocardial infarction, with-
out contribution to myocardial contraction. These non-
specific cellular effects have been studied by introducing
different cell types into the scar lesion, such as smooth
muscle cells. By this passive mechanism, even noncon-
tractile cells such as fibroblasts could be beneficial [79,
89].
Theoretically, the best functional improvement can be
achieved when engrafted stem cells differentiate to car-
diomyocytes, which provide for enhanced contractile per-
formance. When coupled with host myocytes (as demon-
strated by connexin-43 and cadherin staining), they may
create an electromechanical continuum which ensures the
orderly propagation of electrical signals and coordinated
synchronous contractions, which rescue systolic function.
However, thus far, an electromechanical function of
transdifferentiated bone marrow cells in situ has never
been demonstrated, but novel methods could provide
insight in this issue [79, 90].
The improvement in cardiac performance and regional
function may also result from neovascularization induced
by stem cells directly or indirectly, increasing the perfu-
sion of adjacent hibernating host cardiomyocytes [32, 91].
Moreover, this enhanced neovascularization leads to a
reduction of apoptosis of the compensating myocytes in
the peri-infarct region and prevents myocardial fibrosis
with subsequent beneficial effects on postinfarction re-
modeling [72]. In this regard, the beneficial effects of
transplanted stem cells are likely to be attributed to
enhanced revascularization without directly contributing
to systolic contraction, and this could be a major mecha-
nism by which stem cells improve cardiac function [79].
In a recent pilot trial in humans, this enhanced neovascu-
larization may have contributed to an improved left ven-
tricular function. Enhanced neovascularization was sug-
gested by almost complete normalization of the coronary
blood flow reserve and an improved nuclear perfusion
[43]. As already mentioned, it remains unclear whether
stem cell fusion with host cardiac myocytes provide for a
physiological repair mechanism. Theoretically, fused, hy-
brid cells could be intermediates (followed by reduction
divisions) in the regeneration process or fusion of stem
cells could even rescue the threatened residual (peri-)
infarct cardiomyocytes. This issue clearly needs further
investigation.
In most studies, the assays used to evaluate the im-
provement of cardiac function after cellular therapy have
failed to distinguish the different underlying mechanisms
of cardiac improvement. However, it may be of critical
importance to understand these mechanisms when envis-
aging strategies aimed at enhancing cellular intervention
[79].
Adverse Reactions
Stem cells lost due to failure of cardiac engraftment can
home to different organs such as the lungs, liver and many
other organs [92]. The fate of these systemically engrafted
mesenchymal stem cells differentiated to chondrocytes,
adipocytes and bone marrow stromal cells has been
assessed [77]. They also engraft in the brain where they
adopt neural or astrocyte phenotypes [93].
It has also been hypothesized that mesenchymal stem
cells may even be capable in participating in ongoing cel-
lular turnover and replacement within an engrafted organ
[94].
Finally, stem cells such as endothelial progenitors and
multipotent adult progenitor cells (MAPC) have been
demonstrated to incorporate into the angiogenic vascula-
ture of growing tumors [61, 95]. Using isotope labeling in
rats, Gao et al. [92] demonstrated that culture-expanded
mesenchymal stem cells lodge in the lungs after systemic
infusion. The clinical implications of these lodged cells in
the pulmonary system, however, have not yet been criti-
cally evaluated. On the other hand, there has been no sig-
nificant acute toxicity when autologous or allogeneic mes-
enchymal stem cells are administered intravenously in
humans [96].
The fates of stem cells in the different organs at long
term are not known, but in contrast to (undifferentiated)
embryonic stem cells, there are no reports that adult stem
cells can form neoplasms after systemic engraftment (in
small animals with relative short life spans!). However,
when expanded in culture, adult stem cells can dedifferen-
tiate and take on embryonic stem cell properties [97].
Expanding cells in culture could result in unintended
alterations in the intrinsic properties or biological behav-
ior, and cells that have been cultured for long periods may
be dangerous because, theoretically, stem cells cultured in
vitro may accumulate genetic mutations [97]. Finally, the
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reports of stem cell fusion also implicates possible risks
for tumour formation because hybrid, hyperploid cells
may be unstable with ensuing uncontrolled growth [98].
Taking all this into account, one should be aware of the
possible contribution of (undifferentiated) stem cells to
the progress of pathological processes, vascularization of
tumor tissues or even their cancerous transformation [67,
95, 98, 99, 100].
Currently, the realistic prospects for bone marrow
stem cell therapy on a large scale for cardiac repair in
humans appears to be remote and one of the reasons could
be the electrophysiological properties of the engrafted
stem cells. When cultured in vitro, cardiomyocytes de-
rived from mouse embryonic stem cells reveal arrhyth-
mogenic properties with action potential heterogeneity,
protracted automaticity, reentry and frequent sponta-
neous and easily inducible triggered activity [101]. In
addition, the ischemic milieu that surrounds the en-
grafted cells could exacerbate arrhythmogenesis [101]. In
the early embryonic heart, each cell possesses an intrinsic
pacemaker activity and as heart development progresses,
the cells differentiate to atrial or ventricle myocytes and
the overall rhythm is dictated by a small number of pace-
maker cells [102]. This developmental heterogeneity has
also been demonstrated in mesenchymal stem cell cul-
tures with cardiomyogenic commitment [68]. It seems
very likely that during the transdifferentiation process,
the engrafted stem cells in the infarct area not only reca-
pitulate the morphological characteristics but also the dif-
ferent electrophysiological stages of cardiac embryogene-
sis, creating a substrate for arrhythmogenesis in the regen-
erating heart. However, in contrast to skeletal myoblasts,
none of the animal or human experimental studies using
bone marrow stem cells has revealed enhanced malignant
arrhythmias. Several reasons may account for these find-
ings. The first and most obvious reason is that the possible
arrhythmic complications remains to be determined in
the long term. Second, stem-cell-derived cardiomyocytes
may behave differently in vivo than in vitro, being less
arrhythmogenic in vivo [101]. Finally, some studies sug-
gest that the formation of new endothelial cells might be a
more common event than the attempted cardiomyocyte
renewal [10].
Conclusion
Despite many breakthroughs in cardiovascular medi-
cine, the complications of a myocardial infarction such as
chronic congestive heart failure remain a serious world-
wide problem.
Stem cells could provide a promising strategy to repair
myocardial infarctions and prevent postinfarct congestive
heart failure. However, before this regenerative strategy
can be applied in in humans, many questions should be
resolved first.
As with most reviews on stem cells in cardiology, this
review also raises more questions than answers. Which
and how many stem cells are needed to restore an infarct
area? When should stem cells be delivered after myocar-
dial infarction and what kind of delivery method is the
most appropriate? We should also focus on the mecha-
nisms that home stem cells to the heart and how stem cell
differentiation proceeds in the injured heart. How could
we restore a normal extracellular matrix and an optimal
vascular supply in the infarct area? Which adverse reac-
tions could be expected in the short term and in the long
term?
It is clear that as long these questions remain unsolved,
much scientific work needs to be done.
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